-
Sector Analysis
Cell and Gene Therapies in CNS Disorders - Disease Overview, Treatment Options and Future Market Assessment
Currently, there are nine cell and gene therapies (CGTs) on the market for various central nervous system (CNS) disorders. This includes three gene therapies, three gene-modified cell therapies, and three conditionally approved cell therapies. Novartis’s Zolgensma (onasemnogene abeparvovec) for the treatment of spinal muscular atrophy (SMA) was the first CGT asset to receive traditional approval in the CNS market in 2019. Over the past five years, there has been an increase in the number of traditionally approved CGTs for genetic...
-
Thematic Analysis
Neuroimmunology Drug Development - Thematic Research
Neuroimmune communication is complex, bidirectional, and mediated across both neural and humoral pathways. A neuroimmunology drug is an agent that aims to regulate immune system activity to treat neurological diseases with underlying immune pathologies. Of the innovator products marketed for the eight key indications covered in this report, the majority are indicated for multiple sclerosis (MS), followed by neuromyelitis optica spectrum disorder (NMOSD), Alzheimer’s disease (AD), and for myasthenia gravis (MG). Most marketed neuroimmunology products are small molecules, followed by...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.